Clinical Trial Update: Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation [Phase 2]

View source ↗

Summary

Phase 2 trial results on prevention of stroke and systemic embolic events in patients with nonvalvular atrial fibrillation; status completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonvalvular Atrial Fibrillation

Drugs mentioned

• Not specified

Snippet

Sponsor: AstraZeneca | Conditions: Nonvalvular Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2011-09-22